|
|
| |
| Tomita N, Inoue S, Ikeda S. Applicability of HTA in policy decision-making: Part I. J Health Care Community. 2011;21(2):163-174. (in Japanese) |
|
| Iwata N, Ohnishi K, Inoue S. Comparison between the treatment outcomes of monotherapy with new antipsychotic drugs using medical fee receipts. Jap J Clin Psychopharmacol. 2011;14(8):1387-1395. (in Japanese) |
|
| Ikeda S, Ogawa S, Hosokawa T, Murakawa K, Hotta N, Nonno S, Takahashi K, Kikuchi S, Hanaoka K, Kobayashi M. Cost-effectiveness analysis of pregabalin for treatment of peripheral neuropathic pain. Jpn JPharmacoepidemiol. 2011;16(1):1-9. (in Japanese) |
|
Kobayashi M. Advances in methodologies for the economic evaluation of health technologies –lessons from probabilistic approaches–. Pharm Med Device Regul Sci. 2011:42(6);500-507. (in Japanese) |
|
Inoue S. Pharmacoeconomic analysis of Helicobacter pylori eradication therapy. Pharmaceuticals Monthly. 2011;53(2):197-204. (in Japanese) |
|
Sakamaki H, Kobayashi M, Goto M. Cost-comparison analysis of first-generation antihistamine and second-generation antihistamine(fexofenadine) for allergic rhinitis. Med Drug J. 2011;47(1):117-125. (in Japanese) |
|
Kobayashi M. Pharmacoeconomics and health policy. Jpn J Clin Pharmacol Ther. 2010;41(6):265-270. (in Japanese) |
|
Ikeda S, Kobayashi M, Tajima N. Cost-effectiveness analysis of voglibose for prevention of type 2 diabetes mellitus in Japanese patients with impaired glucose tolerance. JDI. 2010;1(6):252-258. |
|
Murata T, Yanoma A, Shiragami M. Cost-effectiveness analysis and healthcare cost estimation through self-medication of a hypothetical over-the-counter antihyperlipidemic drug under the specified health guidance program in Japan. Jpn J Health Econ Policy. 2010;22(1):31-44. (in Japanese) |
|
Kaneko T, Kobayashi M, Inoue S, Hirakawa K. Economic analysis of minimally invasive surgery-total hip arthroplasty in Japan. Orthop surg. 2010;61(10):1117-1121. (in Japanese) |
|
Ikeda S, Kobayashi M. Cost-effectiveness analysis of metformin or pioglitazone combined with sulfonylurea in type 2 diabetes mellitus in Japan. J Jpn Dia Soc. 2010;53(7):469-475. (in Japanese) |
|
Murata T, Kobayashi M, Kudo S. The current situation of COPD patients in Japan based on medical receipt data. Kyunyu-ryoho. 2010;2(2):54-61. (in Japanese) |
|
Tamaki Y, Ohkubo T, Kobayashi M, Sato K, Kikuya M, Obara T, Metoki H, Asayama K, Hirose T, Totsune K, Suzuki K, Imai Y. Cost-effectiveness of hypertension treatment based on the measurement of ambulatory blood pressure. Yakugaku Zasshi. 2010;130(6):805-820. (in Japanese) |
|
Nakahara N, Kamae I, Inagaki A, Kobayashi M. Analysis of the treatment outcomes for schizophrenia using medical fee receipts. Jpn J Clin Psychopharmacol. 2010;13(4):775-785. (in Japanese) |
|
Study Group for Health Economics Frontier; Kamae I, Nagae T, Aoki M, Sannomiya K, Kasai M, Kozaki M, Saijo H, Nakahara N, Mori T, Yokoyama T, Matsushita Y, Mori A, Inoue A, Shibahara T, Tsuda N, Morisaki K, Kobayashi M. IQWiG guideline for health technology assessment. Soc Insur J. 2009;2409:18-25. (in Japanese) |
|
Kobayashi M, Saito I. Economic evaluation of antihypertensive therapy. Doctor-salon library. 2009;53:41-44. (in Japanese) |
|
Inoue S, Okuda S, Yamaguchi T. Socio-economic analysis of edaravone for lacunar infarction. Med Drug J. 2009;45(8):2117-2122. (in Japanese) |
|
Saito I, Kobayashi M, Saruta T. Pharmacoeconomic evaluation of antihypertensive therapy in Japan. Prog Med. 2009;29(2):376-385. (in Japanese) |
|
Saito I, Kobayashi M, Matsushita Y, Mori A, Kawasugi K, Saruta T. Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens Res. 2008;31(7):1373-1383. |
|
| Ikeda S, Kobayashi M. Development of risk simulation software for outcome prediction and economic assessment of diabetes mellitus. APJDM. 2008;2(4):111-118. |
|
| Inoue S, Kobayashi M, Sugaya K. Economic impact of overactive bladder symptoms in Japan. Int J Urology. 2008;99(7):713-722. (in Japanese) |
|
Ishiwada N, Iwata S, Sakata H, Sakano T, Sato Y, Nakano T, Nishi J, Haruta T, Hoshino T, Kamiya H. Burden of illness of pneumonia caused by Streptococcus pneumoniae in children. Jpn J Pediatrics. 2008;61(11):2194-2204. (in Japanese) |
|
| Iwata S, Ishiwada N, Sakata H, Sakano T, Sato Y, Nakano T, Nishi J, Haruta T, Hoshino T, Kamiya H. Burden of illness of bacterial meningitis and bacteremia caused by Streptococcus pneumoniae in children. Jpn J Pediatrics. 2008;61(11):2206-2220. (in Japanese) |
|
Yamanaka N, Hotomi M, Sugita R. Cost-effectiveness of pneumococcal conjugate in Japan: Estimation on acute pneumococcal otitis media in children. Jpn J Pediatrics. 2008;61(11):2221-2232. (in Japanese) |
|
Kamiya H, Iwata S, Ishiwada N, Yamanaka N, Sugita R. Economic analysis of pneumococcal conjugate vaccination in Japan. Jpn J Pediatrics. 2008;61(11):2233-2241. (in Japanese) |
|
| Okubo K, Gotoh M, Fujieda S, Okano M, Yoshida H, Morikawa H, Masuyama K, Okamoto Y, Kobayashi M. A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis. Allergol Int. 2008;57(3):265-275. |
|
| Kobayashi M, Inoue S, Yamauchi K. Clinical efficacy and safety of fexofenadine, loratadine and cetirizine for seasonal allergic rhinitis. Med Drug J. 2008;44(9):2197-2209. (in Japanese) |
|
| Fukunaga H, Ohkubo T, Kobayashi M, Tamaki Y, Kikuya M, Obara T, Nakagawa M, Hara A, Asayama K, Metoki H, Inoue R, Hashimoto J, Totsune K, Imai Y. Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension. J Hypertens. 2008;26(4):685-690. |
|
| Fukunaga H, Ohkubo T, Kobayashi M, Tamaki Y, Kikuya M, Nakagawa M, Obara T, Metoki H, Asayama K, Totsune K, Hashimoto J, Suzuki K, Imai Y. The cost-effectiveness of the introduction of home blood pressure measurement for the diagnosis and treatment of hypertension. Jpn J Health Econ Policy. 2008;19(3):211-232. (in Japanese) |
|
Ikeda S, Kobayashi M. Pharmacoeconomic analysis of HMG-CoA reductase inhibitors for patients with hypercholesterolemia. J Jpn Soc Health Care Manage. 2008;8(4):521-525. (in Japanese) |
|
| Nakahara N, Kobayashi M, Inagaki A. Simulation of psychiatric hospital management by system dynamics. Soc Insur J. 2008;2346:18-22. (in Japanese) |
|
| Fukuda T, Kobayashi M, Nakahara N, Kanba S. Health economics of schizophrenia. Soc Insur J. 2008;2342:20-26. (in Japanese) |
|
| Nakamura M, Yamada N, Kobayashi M, Yamauchi K, Nakano T, Ito M. Health economic analysis of prevention of deep vein thrombosis after stroke. Heart. 2007;39(11):975-983. (in Japanese) |
|
| Ikeda S, Kobayashi M, Makino H. Health economics of use of angiotensin-Ⅱ-receptor blocker in the patients with type 2 diabetes and nephropathy. Hosp Adm. 2007;44(4):353-362. (in Japanese) |
|
| Obara T, Kobayashi M. Evaluation of generic drugs on competitive policy. J Ther. 2007;89(3):527-531. (in Japanese) |
|
| Shinohara Y, Kobayashi M, Umeda T. Medico-economic evaluation for the treatment of acute ischemic stroke using a placebo-controlled clinical trial of fasudil. Jpn J Stroke . 2007;29(1):22-28. (in Japanese) |
|
| Saito I, Kobayashi M, Matsushita Y, Kawasugi K, Saruta T. Pharmacoeconomical evaluation of antihypertensive therapy. Prog Med. 2007;27(1):153-160. (in Japanese) |
|
Kamiya H, Miyazaki C, Nakano T, Sasaki M. Analysis of the disease burden caused by Hib meningitis and cost-effectiveness analysis of Hib vaccine. J Jpn Pediatr Soc. 2006;110(9):1214-1221. |
|
| Funahashi J, Ohkubo T, Fukunaga H, Kikuya M, Takada N, Asayama K, Metoki H, Obara T, Inoue R, Hashimoto J, Totsune K, Kobayashi M, Imai Y. The economic impact of the introduction of home blood pressure measurement for the diagnosis and treatment of hypertension. Blood Press Monit. 2006;11(5):257-267. |
|
|
Mano T, Kobayashi M, Ida H, Yamauchi K, Fujisawa K, Tsukahara Y. Preference of medical student's for medical specialties. Tama Univ J Manag Inform Sci. 2006;10:107-119. (in Japanese) |
|
|
Kobayashi M. Generic drugs and health economics in Japan. Prog Med. 2006;26(5):1025-1030. (in Japanese) |
|
Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, Tachihara A, Nagashima M, Yoshino S, Nakajima A. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol. 2006;16(2):77-84. |
|
Inoue T, Kobayashi M, Uetsuka Y, Uchiyama S. Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction. Circ J. 2006;70(4):453-458. |
|
|
Sunakawa K, Kobayashi M, Goto H, Wada K. Analyses of treatment days and cost of panipenem/betamipron and cefozopran therapy in the treatment of respiratory tract infections. Jpn J Chemother. 2006;54(2):111-124. (in Japanese) |
|
| Saito I, Kobayashi M, Matsushita Y, Saruta T. Pharmacoeconomical evaluation of combination therapy for lifetime hypertension treatment in Japan. JMAJ. 2005;48(12):574-585. |
|
|
Aikawa N, Fujishima S, Kobayashi M, Matsuoka S, Abiru T. Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome. Pharmacoeconomics. 2005;23(2):169-181. |
|
|
Fuji T, Nakamura M, Yamada N, Kobayashi M, Yamauchi K, NakanoT. Health economic analysis of prevention of deep venous thrombosis - An application of pharmacoeconomics-. Clinic all-round (Sogo-Rinsyo). 2005;54(11):2988-2997. (in Japanese) |
|
|
Saito I, Kobayashi M, Matsushita Y. Cost effectiveness of antihypertensive therapy. Prog Med. 2005;25(10):2593-2596. (in Japanese) |
|
Nakamura M, Yamada N, Fuji T, Sakon M, Kobayashi M, Yamauchi K, Nakano T. Strategy for prevention of deep vein thrombosis - An application of clinical decision analysis-. Clinic all-round (Sogo-Rinsyo). 2005;54(8):2339-2345. (in Japanese) |
|
| Nishimura S, Kobayashi M. Cost of COPD and cost-effectiveness of tiotropium in Japan. Pharma Medica. 2005;23(3):165-173. (in Japanese) |
|
|
Funahashi J, Ohkubo T, Kikuya M, Fukunaga H, Kobayashi M. The economic impact of the introduction of home blood pressure measurement for the diagnosis and treatment of hypertension. Jpn J Health Econ Policy. 2005;17:5-20. (in Japanese) |
|
Kitano A, Iishige M, Kobayashi M. Health economics of inflammatory bowel disease. Saishin Igaku. 2005;29(suppl.):174-185. (in Japanese) |
|
Mano T, Mizuno S, Kobayashi M, Ida H, Yamauchi K. Healthcare service: the consideration from the standpoint of service marketing. J Jpn Soc Health Care Manag. 2004;5(3):462-466. (in Japanese) |
|
Mano T, Kobayashi M. Health and pharmacoeconomics and choice of antiulcer drug. J Clinic Exp Med (Igaku no ayumi). 2004;210(5):500-504. (in Japanese) |
|
Okubo K, Gotoh M, Shimada K, Ritsu M, Kobayashi M, and Okuda M. Effect of fexofenadine on the quality of life of Japanese cedar pollinosis patients. Allergol Int. 2004;53(3):245-254. |
|
Kobayashi M, Tomono K, Kohno S. Treatment strategies for patients with community - acquired pneumonia in the outpatient setting -Use of telithromycin-. Jpn J Chemother. 2004;52(3):186-195. (in Japanese) |
|
Mano T, Kobayashi M, Ida H, Yamauchi K, Fujisawa K, Tsukahara Y. Preference of medical students about opening a clinic. J Health Care Community. 2004;14(2):85-102. (in Japanese) |
|
Inomata T, Izumi T, Kobayashi M. Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan. Circ J. 2004;68(1):35-40. |
|
Mano T, Kobayashi M, Ida H, Yamauchi K. The asymmetry of information in medical field and branding. J Jpn Soc Health Care Manag. 2003;4(2):329-334. (in Japanese) |
|
|
Ikeda S, Kobayashi M. Estimation of long-term prognosis of diabetes mellitus: Development of a risk simulation software for economic evaluation. Bunsi-tonyobyo-gaku no sinpo. 2003;191-194. (in Japanese) |
|
|
Saito I, Kobayashi M, Saruta T. Economic analysis of antihypertensive agents in treating patients with essential hypertension. J Clin Thera Med. 2003;19(7):777-788. (in Japanese) |
|
|
Mano T, Mizuno S, Kobayashi M, Yamauchi K. Consumer's idea about medical information. J Jpn Soc Health Care Manag. 2003;3(4):664-667. (in Japanese) |
|
|
Kohno S, Tomono K, Kobayashi M. Burden of community-acquired pneumonia in Japan. Jpn J Chemother. 2003;51(3):107-114. (in Japanese) |
|
|
Fujishima S, Aikawa N, Kobayashi M, Matsuoka S, Abiru T. Cost analysis of ONO-5046 Na in acute lung injury with SIRS. Jpn J Clinical Exp Med. 2002;79(7):1251-1258. (in Japanese) |
|
Moriguchi H, Uemura T, Kobayashi M, Chung RT, Sato C. Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis. Hepatology. 2002;36(1):177-185. |
|
|
Sugano K, Kobayashi M. Economic evaluation of maintenance therapies for reflux esophagitis -Comparison between step-up therapies and step-down therapies-. Jpn Pharmacol Thra. 2001;29(6):459-468. (in Japanese) |
|
|
Revicki DA, Kobayashi M, Palmer C, Marciniak MD, Hisasige A, Takeda M. Burden of schizophrenia in Japan -Impact on patients, families and society-. Schizophr Front. 2001;2(1):41-49. (in Japanese) |
|
|
Mano T, Kobayashi M. Pharmacoeconomics in United States and Japan. J Ther. 2000;82(12):3047-3050. (in Japanese) |
|
|
Watanabe A, Kobayashi M. Socioeconomic analysis of oseltamivir for influenza patients. Jpn J Chemother. 2001;49(2):95-102. (in Japanese) |
|
Iino S, Yasuda K, Kobayashi M, Fujino S, Ogawa K. Cost-effective analysis of IFN treatment in chronic hepatitis C. Jpn Med J. 1998;3870:10-15. (in Japanese) |
| |
|
|
